Lori Austin, MD
Internal Medicine · Cookeville, TNNPI 1336133248
Payments from drug & device makers
Across 183 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$550
- Pfizer$349
- GSK$279
- Lilly USA, LLC$259
- Novartis$214
- Amgen$190
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$2,97799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $550 |
| Pfizer | 26 | $349 |
| GSK | 15 | $279 |
| Lilly USA, LLC | 17 | $259 |
| Novartis | 14 | $214 |
| Amgen | 13 | $190 |
| Astellas Pharma US Inc | 11 | $183 |
| AstraZeneca | 6 | $104 |
| Kls-martin L.p. | 4 | $102 |
| AbbVie | 4 | $86 |
| Johnson & Johnson | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Boehringer Ingelheim | 3 | $60 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 3 | $42 |
| Merck | 2 | $36 |
| Bayer | 2 | $34 |
| Dexcom, Inc. | 2 | $30 |
| Exact Sciences | 2 | $30 |
| Boston Scientific | 1 | $24 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Medtronic | 1 | $20 |
| Abbott | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$3,000 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $218,552 |
| EliquisApixaban | 150 | $165,368 |
| JardianceEmpagliflozin | 104 | $98,798 |
| XareltoRivaroxaban | 56 | $60,278 |
| MounjaroTirzepatide | 53 | $57,962 |
| JanuviaSitagliptin Phosphate | 40 | $40,199 |
| MyrbetriqMirabegron | 42 | $35,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,473 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,173 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $11,054 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $10,117 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,484 |
| Tolterodine Tartrate ErTolterodine Tartrate | 57 | $9,108 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $8,450 |
| Atorvastatin Calcium | 689 | $8,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $550 | $218,552183 claims |
| PfizerEliquis | $349 | $165,368150 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $60 | $109,853123 claims |
| Johnson & JohnsonXarelto | $73 | $60,27856 claims |
| Lilly USA, LLCMounjaro | $259 | $57,96253 claims |
| MerckJanuvia | $36 | $40,19940 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $35,71542 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $279 | $31,64650 claims |
| Sanofi-aventis U.S. LLCLantus | $51 | $7,12315 claims |
| AstraZenecaPulmicort Flexhaler | $104 | $4,89613 claims |
| AbbVieSynthroid | $86 | $2,74763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Cookeville
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.